TransCode Therapeutics Inc (RNAZ) USD0.0001

Sell:$10.93Buy:$12.00$0.25 (2.28%)

Prices delayed by at least 15 minutes
Sell:$10.93
Buy:$12.00
Change:$0.25 (2.28%)
Deal now
Prices delayed by at least 15 minutes
Sell:$10.93
Buy:$12.00
Change:$0.25 (2.28%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Key people

Philippe P. Calais
Executive Chairman of the Board, Chief Executive Officer
Thomas A. Fitzgerald
Chief Financial Officer, Vice President, Director
Daniel Vlock
Chief Medical Officer
Elizabeth Czerepak
Independent Director
Erik Manting
Independent Director
Magda Marquet
Independent Director
Click to see more

Key facts

  • Shares in issue
    916,968.00
  • EPIC
    RNAZ
  • ISIN
    US89357L5012
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $10.04m
  • Employees
    7
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.